- Home
- CRBP vs NAUT Comparison
CRBP vs NAUT Comparison
Compare CRBP & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- NAUT
- Stock Information
- Founded
- CRBP 2009
- NAUT 2016
- Country
- CRBP United States
- NAUT United States
- Employees
- CRBP N/A
- NAUT N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- NAUT Biotechnology: Laboratory Analytical Instruments
- Sector
- CRBP Health Care
- NAUT Industrials
- Exchange
- CRBP Nasdaq
- NAUT Nasdaq
- Market Cap
- CRBP 110.3M
- NAUT 95.6M
- IPO Year
- CRBP N/A
- NAUT N/A
- Fundamental
- Price
- CRBP $9.79
- NAUT $0.70
- Analyst Decision
- CRBP Strong Buy
- NAUT Strong Sell
- Analyst Count
- CRBP 10
- NAUT 1
- Target Price
- CRBP $53.22
- NAUT $1.75
- AVG Volume (30 Days)
- CRBP 107.9K
- NAUT 203.3K
- Earning Date
- CRBP 08-05-2025
- NAUT 07-31-2025
- Dividend Yield
- CRBP N/A
- NAUT N/A
- EPS Growth
- CRBP N/A
- NAUT N/A
- EPS
- CRBP N/A
- NAUT N/A
- Revenue
- CRBP N/A
- NAUT N/A
- Revenue This Year
- CRBP N/A
- NAUT N/A
- Revenue Next Year
- CRBP $270.04
- NAUT N/A
- P/E Ratio
- CRBP N/A
- NAUT N/A
- Revenue Growth
- CRBP N/A
- NAUT N/A
- 52 Week Low
- CRBP $4.64
- NAUT $0.66
- 52 Week High
- CRBP $61.89
- NAUT $3.09
- Technical
- Relative Strength Index (RSI)
- CRBP 62.32
- NAUT 44.44
- Support Level
- CRBP $8.88
- NAUT $0.67
- Resistance Level
- CRBP $9.59
- NAUT $0.76
- Average True Range (ATR)
- CRBP 0.59
- NAUT 0.04
- MACD
- CRBP 0.03
- NAUT -0.00
- Stochastic Oscillator
- CRBP 78.45
- NAUT 29.29
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.